AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas

Khasraw, M; Hofman, MS; Chantrill, L; Pavlakis, N; Gebski, V; Gill, AJ; Markman, B; Yip, S; Gibbs, E; Karapetis, C; Wong, SF; Ransom, DT; Michael, M; Wilson, K; Simes, J; Lipton, L

AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas

conference contribution

posted on 2024-06-19, 00:51 authored by M Khasraw, MS Hofman, L Chantrill, N Pavlakis, V Gebski, AJ Gill, B Markman, S Yip, E Gibbs, C Karapetis, SF Wong, DT Ransom, M Michael, K Wilson, J Simes, L Lipton

AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas

History

Volume

28

Location

Madrid, SPAIN

Start date

2017-09-08

End date

2017-09-12

ISSN

0923-7534

eISSN

1569-8041

Language

English

Author URL

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324001127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a045e4b2bb1f2b747c68c720ec8913b7

Publication classification

E3 Extract of paper

Title of proceedings

ANNALS OF ONCOLOGY

Event

42nd European-Society-for-Medical-Oncology Congress (ESMO)

Publisher

OXFORD UNIV PRESS

Usage metrics

Keywords

Science & Technology Life Sciences & Biomedicine Oncology 111299 Oncology and Carcinogenesis not elsewhere classified 3211 Oncology and carcinogenesis

AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas

History

Volume

Location

Start date

End date

ISSN

eISSN

Language

Author URL

Publication classification

Title of proceedings

Event

Publisher

Usage metrics

Categories

Keywords

Licence

Exports